Stage IV ALK+ NSCLCs form a distinct clinical and demographic patient group, when compared to the general NSCLC population and evaluating the metastatic patterns can provide a better understanding about the disease progression. The gene discussed is ALK; the disease is non-small cell lung carcinoma.